glimepiride: clinical use

Prescribing considerations

• Assess hypoglycaemia risk, including irregular meals, fasting, alcohol, activity or weight changes, renal impairment and interacting medicines.
• Review treatment requirements as glycaemic control and insulin sensitivity change.
• Acute illness, fever, surgery or trauma may require temporary reassessment of diabetes management.
• Paediatric safety and efficacy evidence is insufficient; the selected product does not recommend paediatric use.
• Consider a non-sulphonylurea alternative in G6PD deficiency because of haemolytic anaemia risk.

Contraindications and cautions

• Hypersensitivity to glimepiride, other sulphonylureas, sulfonamides or product excipients.
• Type 1 diabetes, diabetic ketoacidosis or diabetic coma.
• Severe renal or hepatic impairment.
• Rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption because the selected tablet contains lactose.

Monitoring

• Monitor glycaemic control, including glucose and glycated haemoglobin.
• Monitor for hypoglycaemia and reduced awareness, particularly after clinical or medicine changes.
• The selected product information requires hepatic and haematological monitoring, especially leucocytes and platelets.
• Review renal and hepatic function and investigate symptoms suggesting liver or blood-cell toxicity.

Clinical pharmacology

Glimepiride is a highly protein-bound sulphonylurea metabolised mainly through CYP2C9 to hydroxy and carboxy metabolites. Its main effect is glucose-responsive pancreatic insulin release, with described effects on glucose uptake and hepatic glucose production.

Formulation and product differences

• The selected product is a light-blue, capsule-shaped tablet marked “GM” and “4”, with score lines allowing division into equal halves.
• The selected tablet contains lactose monohydrate and indigo carmine aluminium lake.

Tablet

Route: Oral

Strengths: 1 mg, 2 mg, 3 mg, 4 mg